Literature DB >> 16225179

Transient edematous lesions of the splenium in epileptic patients.

Giovanna Carrara1, Edoardo Ferlazzo, Donatella Tampieri, Frederick Andermann, Denis Melanson.   

Abstract

BACKGROUND: Transient focal lesions in the splenium of the corpus callosum (SCC) have been previously described in patients with epilepsy or without epilepsy but receiving antiepileptic drugs (AED). CASE REPORTS: Two epileptic patients were admitted to our long-term monitoring unit. Antiepileptic drugs were completely discontinued a few days later. One patient had no seizures. The other had three attacks, the last of which occurred two days before a brain magnetic resonance imaging (MRI) was performed. In both cases brain MRI showed a lesion in the SCC characterized by high signal on T2-weighted images and no enhancement after Gadolinium infusion. The patients were discharged with their pre-admission medications. A follow-up MRI five weeks later showed resolution of the SCC lesions.
CONCLUSIONS: The pathogenesis of transient SCC lesions in epileptic patients is still unclear. In our patients, either the sudden AED withdrawal or the seizures activity may be presumed to be the cause, though an individual susceptibility must also be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225179     DOI: 10.1017/s0317167100004261

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  2 in total

1.  Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal.

Authors:  Lingling Wang; Xiaoshan Wang; Xiangsong Shi; Wenchao Qiu; Ailiang Miao
Journal:  Neurol Sci       Date:  2016-11-19       Impact factor: 3.307

2.  Unusual combination of reversible splenial lesion and meningitis-retention syndrome in aseptic meningomyelitis.

Authors:  Nida Tascilar; Hande Aydemir; Ufuk Emre; Aysun Unal; H Tugrul Atasoy; Sureyya Ekem
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.